URAH Micellar: The Solution from Singapore That Has Delivered for over 25 Years
Many find traditional approaches—pills, gels, braces, and repeated injections—bring only partial or temporary relief from joint, bone, or cartilage discomfort. When discomfort persists, surgery is often presented as the next step, even though it is rarely the preferred option.
Common Limitations of Standard Treatments
Patients frequently report recurring challenges:
-
Stiffness after rest and reduced range of motion.
-
Grinding, creaking, or swelling after activity.
-
Reliance on multiple daily pills that upset the stomach or cause other side effects.
-
Short-term benefit from injections followed by the same limitations.
-
Growing concern about long-term joint wear and invasive treatment options.
For those experiencing these limitations, the fundamental issue is that most solutions fail to address the root cause of joint, bone, and cartilage problems—how the active ingredients are delivered into the body.
While many compounds show promise in laboratory settings, they lose effectiveness when converted to pill form. Up to 90-95% of oral glucosamine is lost through various biological processes—the liver and other organs use or break down the active ingredient before it reaches joints, leaving only 5-10% available for cartilage support. Additionally, high doses of glucosamine are naturally acidic, causing gastric irritation, nausea, heartburn, diarrhea, bloating, and potentially gastric ulcers with prolonged use—creating an additional set of problems that also require attention.
In 1999, URAH Labs, a leading life sciences research company based in Singapore, recognized this critical delivery problem and committed to developing an alternative method for delivering active ingredients to maximize benefits for joints, bones, and cartilage.
This seemingly simple shift in approach, using its proprietary micellar delivery technology, that was patented in the USA, Singapore, and Japan—has produced dramatic improvements in long-term joint, bone, and cartilage care outcomes by delivering support directly to affected areas rather than relying on systemic treatments that impact the entire body and may cause side effects.
URAH Bio-Active Micellar Creams
The latest URAH bio-active micellar creams represent 25+ years of research and development, with validation through multiple independent studies.
Currently recommended in hospitals and clinics, these formulations use URAH's proprietary micellar delivery system (URAH MD-Tech) to transport active ingredients effectively into the bloodstream resulting in unparalleled results for users.
Lower daily dosage, Higher Impact
-
One fingertip amount (~0.5g) per day
-
Lower dose, higher impact through targeted application
-
Replaces multiple pills while avoiding systemic side effects
Advanced Proprietary Delivery Technology
-
URAH MD-Tech enhances local delivery versus pills
-
Comparative studies demonstrate up to 10× higher bioavailability
-
Bio-active formulation without cooling or heating placebo sensations
Clinical Validation
-
Clinically tested formula with extensive real-world safety record
-
25+ years of research and development
-
No reported side effects in clinical studies
Research and Clinical Evidence
Bioavailability Studies
Comparative testing demonstrated up to 10× higher detectable levels with URAH micellar delivery versus standard pills in plasma/tissue sampling.
Structural Measurements
Mean medial joint space width increased from 0.49 mm to 0.79 mm after 12 weeks of URAH micellar cream use—about 61%.* (Hong Kong Physiotherapy Journal, 2018).
Multi-Clinic Evaluation
Clinical assessment across 16 clinics reported high participant satisfaction and meaningful symptom improvement within weeks, with no study-reported side effects.
What a typical course looks like
• Days 1–7
Application routine established. Many participants experience relief within hours or days, depending on condition severity.
• Weeks 2–4
Participants commonly report significant increases in comfort for affected joints, with improved flexibility and mobility.
• Weeks 8–12
By week 12, the knee study recorded an increase in mean medial joint space width in the relevant treatment group. This is an indirect structural finding, not direct proof that participants grew new cartilage.
Individual responses vary based on biological factors; consistent use enhances benefits.
Why Healthcare Professionals Recommend URAH
-
Targeted delivery: Active ingredients directed toward joint, bone, and cartilage tissues instead of systemic distribution
-
Higher local uptake: Comparative data supports markedly greater tissue availability versus pills
-
Measurable outcomes: Studies report structural markers and functional improvements—a 61% increase in joint space width
-
Long-standing validation: 25+ years of R&D, hospital recommendations, and institutional recognition
Contains Proprietary micellar delivery technology that was patented in USA, Singapore and Japan
Recommended in Hospitals and Clinics • Clinically proven
Lowest Price Guarantee • 60-Day Money-back Guarantee
